WEBSITE BSE:544694 NSE: ANL Inc. Year: 2021 Industry: Pharmaceuticals & Drugs My Bucket: Add Stock
Last updated: 11:16
No Notes Added Yet
Accretion Nutraveda Ltd is an India based company engaged in the business of nutrition food products and nutraceuticals. The company focuses on manufacturing marketing and distribution of dietary supplements health foods herbal formulations and functional food ingredients that support wellness weight management immunity and overall health. Its product portfolio includes protein powders vitamins minerals herbal extracts probiotics and other fortified nutrition products sold under its own brands as well as through third party manufacturing and pr...Read More
Accretion Nutraveda Ltd is an India based company engaged in the business of nutrition food products and nutraceuticals. The company focuses on manufacturing marketing and distribution of dietary supplements health foods herbal formulations and functional food ingredients that support wellness weight management immunity and overall health. Its product portfolio includes protein powders vitamins minerals herbal extracts probiotics and other fortified nutrition products sold under its own brands as well as through third party manufacturing and private label arrangements. Accretion Nutraveda works with retail distributors e commerce platforms pharmacies nutrition stores and health professionals to expand its market reach in both domestic and export markets. The company emphasises quality control research formulation and regulatory compliance to meet industry standards and consumer expectations in the fast growing health and wellness segment. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹175 Cr.
Stock P/E 67.1
P/B 4.9
Current Price ₹242.3
Book Value ₹ 49
Face Value 10
52W High ₹288
Dividend Yield 0%
52W Low ₹ 150.1
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|
| Net Sales | 3 | 5 | 16 | |
| Other Income | 0 | 0 | 0 | |
| Total Income | 3 | 5 | 16 | |
| Total Expenditure | 2 | 4 | 12 | |
| Operating Profit | 1 | 1 | 4 | |
| Interest | 0 | 0 | 0 | |
| Depreciation | 0 | 0 | 0 | |
| Exceptional Income / Expenses | 0 | 0 | 0 | |
| Profit Before Tax | 0 | 1 | 3 | |
| Provision for Tax | 0 | 0 | 1 | |
| Profit After Tax | 0 | 1 | 3 | |
| Adjustments | 0 | 0 | 0 | |
| Profit After Adjustments | 0 | 1 | 3 | |
| Adjusted Earnings Per Share | 0.8 | 2.3 | 5.4 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 220% | 0% | 0% | 0% |
| Operating Profit CAGR | 300% | 0% | 0% | 0% |
| PAT CAGR | 200% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | NA% | NA% | NA% | NA% |
| ROE Average | 81% | 103% | 103% | 103% |
| ROCE Average | 57% | 40% | 40% | 40% |
| #(Fig in Cr.) | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Shareholder's Funds | 0 | 1 | 5 |
| Minority's Interest | 0 | 0 | 0 |
| Borrowings | 1 | 1 | 2 |
| Other Non-Current Liabilities | 0 | 0 | 0 |
| Total Current Liabilities | 2 | 3 | 4 |
| Total Liabilities | 4 | 5 | 11 |
| Fixed Assets | 1 | 1 | 2 |
| Other Non-Current Assets | 0 | 0 | 0 |
| Total Current Assets | 3 | 3 | 9 |
| Total Assets | 4 | 5 | 11 |
| #(Fig in Cr.) | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 |
| Cash Flow from Operating Activities | 1 | 0 | -2 |
| Cash Flow from Investing Activities | -0 | -0 | -1 |
| Cash Flow from Financing Activities | -1 | -0 | 3 |
| Net Cash Inflow / Outflow | 0 | 0 | -0 |
| Closing Cash & Cash Equivalent | 0 | 0 | 0 |
| # | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Earnings Per Share (Rs) | 0.78 | 2.28 | 5.37 |
| CEPS(Rs) | 1.64 | 3.01 | 5.86 |
| DPS(Rs) | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 0.73 | 3.01 | 10.98 |
| Core EBITDA Margin(%) | 21.41 | 24.45 | 23.26 |
| EBIT Margin(%) | 16.48 | 23.06 | 22.09 |
| Pre Tax Margin(%) | 9.9 | 18.27 | 19.88 |
| PAT Margin (%) | 9.67 | 16.42 | 16.33 |
| Cash Profit Margin (%) | 20.39 | 21.65 | 17.84 |
| ROA(%) | 6.91 | 18.9 | 33.71 |
| ROE(%) | 106.65 | 121.94 | 81.22 |
| ROCE(%) | 21.4 | 42 | 56.72 |
| Receivable days | 100.61 | 38.28 | 40.1 |
| Inventory Days | 162.84 | 133.99 | 79.49 |
| Payable days | 354.92 | 161.86 | 30.77 |
| PER(x) | 0 | 0 | 0 |
| Price/Book(x) | 0 | 0 | 0 |
| Dividend Yield(%) | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.77 | 0.48 | 0.27 |
| EV/Core EBITDA(x) | 2.85 | 1.71 | 1.15 |
| Net Sales Growth(%) | 0 | 72.41 | 219.7 |
| EBIT Growth(%) | 0 | 141.17 | 206.37 |
| PAT Growth(%) | 0 | 192.91 | 217.9 |
| EPS Growth(%) | 0 | 192.93 | 134.99 |
| Debt/Equity(x) | 7.5 | 2 | 0.72 |
| Current Ratio(x) | 1.07 | 1.07 | 2.24 |
| Quick Ratio(x) | 0.53 | 0.29 | 1.08 |
| Interest Cover(x) | 2.5 | 4.82 | 9.96 |
| Total Debt/Mcap(x) | 0 | 0 | 0 |
| # | Dec 2025 | Feb 2026 | Mar 2026 |
|---|---|---|---|
| Promoter | 0 | 73.48 | 73.48 |
| FII | 0 | 6.04 | 1.08 |
| DII | 0 | 6.51 | 7 |
| Public | 0 | 13.98 | 18.44 |
| Others | 0 | 0 | 0 |
| Total | 0 | 100 | 100 |
| # | Dec 2025 | Feb 2026 | Mar 2026 |
|---|---|---|---|
| Promoter | 0 | 0.53 | 0.53 |
| FII | 0 | 0.04 | 0.01 |
| DII | 0 | 0.05 | 0.05 |
| Public | 0 | 0.1 | 0.13 |
| Others | 0 | 0 | 0 |
| Total | 0 | 0.72 | 0.72 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
